Effects of Fufang Biejia Ruangan Pills on hepatic fibrosis in vivo and in vitro

doi:10.3748/wjg.v19.i32.5326

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 19, Issue 32

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6384)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-3) series.

Item

Count

PDF

380

HTML

4101

Figures (1-3)

158

Tables (1-3)

123

Sum=4762

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

842

Download

780

Sum=1622

Aug 28, 2013 (publication date) through Apr 18, 2024

Times Cited of This Article

Times Cited (22)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Aug 28, 2013; 19(32): 5326-5333
Published online Aug 28, 2013. doi: 10.3748/wjg.v19.i32.5326

Table 1 Effect of Fufang Biejia Ruangan Pill on serum levels (mean ± SD)

Group	ALT(U/L)	AST(U/L)	PCIII (μg/mL)	HA (ng/mL)	LN (ng/mL)	CIV (ng/mL)
Control	23.8 ± 8.5^b	30.0 ± 11.4^b	15.16 ± 15.12^b	205.30 ± 48.92^a	82.02 ± 8.86	21.71 ± 1.76
Model	62.0 ± 23.7	98.8 ± 40.0	35.73 ± 17.90	563.82 ± 335.54	89.57 ± 7.59	29.20 ± 6.17
FFBJRGP-treated	50.02 ± 3.7	57.2 ± 30.0^b	30.18 ± 9.41	456.18 ± 410.83	85.46 ± 7.51	28.02 ± 9.45
Colchicine-treated	46.1 ± 14.8	66.0 ± 33.2^a	34.08 ± 9.19	313.17 ± 230.06^a	88.61 ± 8.97	29.22 ± 7.95

^aP < 0.05,

^bP < 0.01 vs model group. ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; PCIII: Type III procollagen; HA: Hyaluronic acid; LN: Laminin; CIV: Type IV collagen; FFBJRGP: Fufang Biejia Ruangan Pill.

Table 2 Liver histopathological semiquantitative scores (mean ± SD)

Group	n	Scores					Staging scores
Group	n	0	I	II	III	IV	Staging scores
Control	6	6					0.00 ± 0.00^b
Model	13				2	11	26.08 ± 5.85
FFBJRGP-treated	9				4	5	20.33 ± 6.12^b
Colchicine-treated	9		1	3	5	2	19.00 ± 6.38^b

^bP < 0.01 vs model group. FFBJRGP: Fufang Biejia Ruangan Pill.

Table 3 Expression of transforming growth factor-β1 and Smad3 (mean ± SD)

Groups	TGF-β1/β-actin	Smad3/β-actin
Control	1.00 ± 0.00^b	0.62 ± 0.08^b
Model	3.29 ± 2.08	1.33 ± 0.10
FFBJRGD-treated	2.08 ± 0.57	0.95 ± 0.12^b
Colchicine-treated	2.25 ± 0.82	1.15 ± 0.06^b

^bP < 0.01 vs model group. TGF-β: Transforming growth factor-β; FFBJRGP: Fufang Biejia Ruangan Pill.

Citation: Yang FR, Fang BW, Lou JS. Effects of Fufang Biejia Ruangan Pills on hepatic fibrosis in vivo and in vitro. World J Gastroenterol 2013; 19(32): 5326-5333
URL: https://www.wjgnet.com/1007-9327/full/v19/i32/5326.htm
DOI: https://dx.doi.org/10.3748/wjg.v19.i32.5326